<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077633</url>
  </required_header>
  <id_info>
    <org_study_id>OBX0038</org_study_id>
    <nct_id>NCT03077633</nct_id>
  </id_info>
  <brief_title>Cerclage for Twins With Short Cervix</brief_title>
  <official_title>Cervical Cerclage for Twin Pregnancy With Sonographic Cervical Length 0.1 to 15.0 mm: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mednax Center for Research, Education and Quality</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mednax Center for Research, Education and Quality</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized control trial that will compare cervical cerclage plus vaginal
      progesterone to vaginal progesterone along in twin pregnancies complicate by a short cervix
      (&lt;/= 15.0mm) between 16w0d to 25w6d.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective Randomized Trial that will test whether treatment with cervical cerclage plus
      vaginal progesterone improves pregnancy outcomes among women with twin pregnancy at 16 0/7
      to 25 6/7 weeks of gestation who have a cervical length (CL) of 0.1 to 15.0 mm on
      transvaginal ultrasound exam, the rate of preterm birth at less than 32 weeks of gestation
      (PTB&lt;32 wks.) and the rate of adverse perinatal outcome will be lower in those treated with
      cervical cerclage plus vaginal progesterone than in those treated with vaginal progesterone
      alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups: Cerclage + Progesterone vs. Progesterone alone</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of very preterm birth (PTB)</measure>
    <time_frame>Time frame measured on the date the infant is born. We anticipate this time frame to be approximately 16 weeks.</time_frame>
    <description>Rate of very PTB (PTB less than 32 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse perinatal outcome</measure>
    <time_frame>Time frame measured 28 days after the infant is born. We anticipate this time frame to be approximately 28 weeks.</time_frame>
    <description>The rate of adverse perinatal outcome defined as any one or more of the following: Miscarriage, stillbirth, neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage (grade III or IV), necrotizing enterocolitis, culture proven sepsis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Preterm Labor With Preterm Delivery, Unspecified Trimester, Fetus 2</condition>
  <condition>Cervical Incompetence</condition>
  <condition>Cervical Shortening</condition>
  <arm_group>
    <arm_group_label>Cervical Cerclage + Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily administration of vaginal progesterone (200mg tab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervical Cerclage placement</intervention_name>
    <description>Surgical placement of a cervical cerclage</description>
    <arm_group_label>Cervical Cerclage + Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Progesterone</intervention_name>
    <description>200mg tab of vaginal progesterone administered daily from time of randomization until delivery.</description>
    <arm_group_label>Cervical Cerclage + Progesterone</arm_group_label>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Prometrium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twin pregnancy (see Exclusion Criterion (a) below re: monochorionic twins)

          -  Gestational age 16 0/7 to 25 6/7 weeks at time of enrollment by best-estimated age.

          -  Cervical length 0.1 to 15.0 mm on transvaginal ultrasound examination. (Cervical
             length is taken to mean the length of the closed portion of the cervical canal.

        Exclusion Criteria:

          -  Maternal age less than 18 years

          -  Monochorionic twins (such as monochorionic-diamniotic, monochorionic-monoamniotic, or
             conjoined twins)

          -  Rupture of membranes, either twin

          -  One or both twins has no cardiac activity

          -  One or both twins has known or suspected major malformation, aneuploidy, or
             polyhydramnios

          -  Maternal congenital uterine anomaly (such as bicornuate uterus, unicornuate uterus)

          -  Pregnancy started as triplets or higher-order multifetal gestation and then reduced
             to twins, either spontaneously or via procedure

          -  Symptomatic uterine contractions, 6 or more per hour

          -  Ongoing bleeding from uterus

          -  Patient declines to consider cerclage

          -  Patient declines treatment with vaginal progesterone

          -  Allergy to progesterone or peanuts (because the vaginal progesterone formulation used
             will be a capsule of micronized progesterone in peanut oil.)

          -  Cerclage is already in place

          -  Cerclage placement is judged to be technically impossible

          -  Patient has a history of poor follow-up or poor adherence to physician
             recommendations

          -  Patient is planning to relocate outside the local area before the end of pregnancy
             such that delivery records will be unavailable

          -  Patient does not give consent to participate in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Combs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mednax Center for Research, Education and Quality</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Maurel, RN</last_name>
    <phone>7143567328</phone>
    <email>kimberly_maurel@mednax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Marusiak, RN</last_name>
    <phone>4809495957</phone>
    <email>barbara_marusiak@mednax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Desert Medical Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana B Braescu, RN, MSN</last_name>
      <phone>602-257-8118</phone>
      <phone_ext>135</phone_ext>
      <email>Ana_braescu@PEDIATRIX.COM</email>
    </contact>
    <investigator>
      <last_name>Jordan Perlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Braescu, MSN</last_name>
      <phone>602-614-0488</phone>
      <email>ana_braescu@mednax.com</email>
    </contact>
    <investigator>
      <last_name>Jordan Perlow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Combs, MD</last_name>
      <phone>408-371-7111</phone>
      <email>andrew_combs@pediatrix.com</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Mallory, RN</last_name>
      <phone>408-371-7111</phone>
      <email>kimberly_mallory@pediatrix.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Combs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kent Heyborne, MD</last_name>
      <phone>303-602-9715</phone>
      <email>Kent.Heyborne@dhha.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Maurel, MSN</last_name>
      <phone>714-593-9171</phone>
      <email>kimberly_maurel@mednax.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kent Heyborne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Adair, MD</last_name>
      <phone>423-664-4460</phone>
    </contact>
    <contact_backup>
      <last_name>Lorrie Mason, RN</last_name>
      <phone>423-664-4460</phone>
      <email>lorrie@rocob.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Adair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Children's Hospital-Texas Center for Fetal Assessment</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeroen Vanderhoeven, MD</last_name>
      <phone>206-386-2101</phone>
      <email>jeroen_vanderhoeven@mednax.com</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Artis, RN</last_name>
      <phone>206-215-3541</phone>
      <email>dawn_artis@pediatrix.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeroen Vanderhoeven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerclage</keyword>
  <keyword>Cervical shortening</keyword>
  <keyword>Twins</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
    <mesh_term>Uterine Cervical Incompetence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
